MedPath

Benefits of High Flow Nasal Cannula Oxygen for Preoxygenation During Intubation in Non Severely Hypoxemic Patients

Not Applicable
Completed
Conditions
Need for Intubation, No Severe Hypoxemia
Interventions
Procedure: STANDARD Face Mask
Device: OPTIFLOW/ AIRVO
Registration Number
NCT02700321
Lead Sponsor
Nantes University Hospital
Brief Summary

The aim of this study is to determine whether High Flow nasal cannula (HFNC) oxygen is more efficient than the standard High Flow face mask (HFFM) for preoxygenation before orotracheal intubation after crash induction in non severely hypoxemic patients

Detailed Description

This study will be designed as followed : patients will be randomized in 2 groups : High Flow nasal cannula "HFNC" or standard High Flow face mask "HFFM".

Patients randomized in "HFNC" group will receive a four minutes preoxygenation period with Nasal High Flow Therapy (60 L/mn , fraction of inspired oxygen (FI02) = 100%) before orotracheal intubation under laryngoscopy after crash induction. After induction and during laryngoscopy, HFNC will be maintained in an attempt to achieve apneic oxygenation.

Patients randomized in "HFFM" group will received a four minutes preoxygenation period with standard face mask (15 L/mn) before orotracheal intubation under laryngoscopy after crash induction. After induction, HFFM will be removed, enabling laryngoscopic vision

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
192
Inclusion Criteria
  • Adults older than 18 years regardless of the gender
  • Requiring orotracheal intubation in intensive care unit
  • "No severely hypoxemic respiratory failure" defined as Oxygen Pression (Pa02)/FI02 > 200 mmHg measured in the 4 hours before inclusion
Exclusion Criteria
  • Not the first Intubation during this stay in intensive care unit
  • Contraindication to oro-tracheal intubation
  • Intubation without anaesthesic rapid sequence induction
  • Intubation during cardiac arrest
  • Real emergency (as asphyxia) with immediate intubation needed (without time enough for randomization)
  • Nasopharyngeal obstacle with contraindication to use Optiflow device
  • Patients with a documented Cormack IV exposition before inclusion
  • Protected adult
  • Pregnancy or breastfeeding
  • Lack of consent
  • Patient already enrolled in another study that could interfere with the primary objective of this study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
STANDARD high flow Face Mask (HFFM)STANDARD Face MaskPatients randomized in "Standard face mask" group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction.
High Flow nasal cannula oxygen (HFNC)OPTIFLOW/ AIRVOPatients randomized in "HFNC" group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow 庐/Airvo庐 (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction.
Primary Outcome Measures
NameTimeMethod
lowest pulse oxymetry (SpO2) during intubationFrom the beginning of the endotracheal intubation procedure (beginning of laryngoscopy, immediately after induction) to completed orotracheal intubation (airway catheterization). Usual duration is inferior to 10 minutes

This outcome will be assessed from the beginning of the endotracheal intubation procedure (immediately after induction) to the end of orotracheal intubation (airway catheterization) by monitoring the pulse oxymetry

Secondary Outcome Measures
NameTimeMethod
SOFA scoreEach day during the 5 first days after randomisation
number of desaturation events (under 80%)From the beginning of the endotracheal intubation procedure (beginning of laryngoscopy, immediately after induction) to completed orotracheal intubation (airway catheterization). Usual duration is inferior to 10 minutes)
Pulse oximetryfrom the beginning of preoxygenation period to the end of intubation procedure. Usual duration is inferior to 15 minutes
Reduction in morbi-mortality during the Intensive care Unit stayfrom beginning of the preoxygenation period to discharged from intensive care unit (until day 28 for more)

Trial Locations

Locations (8)

Nantes university hospital, h么tel Dieu, Anesthesia intensive care unit

馃嚝馃嚪

Nantes, France

Brest hospital, CHU La cavale Blanche, medical intensive care unit

馃嚝馃嚪

Brest, France

CHD LES OUDOUAIRIES Service de r茅animation polyvalente

馃嚝馃嚪

La Roche Sur Yon, France

Ch Le Mans

馃嚝馃嚪

Le Mans, France

Nantes University Hospital, H么tel Dieu, Medical intensive care unit

馃嚝馃嚪

Nantes, France

Rennes university hospital, H么pital Pontchaillou, medical intensive care unit

馃嚝馃嚪

Rennes, France

Nantes University hospital, H么pital Laennec, pneumology intensive care unit

馃嚝馃嚪

St Herblain, France

Tours university hospital, h么pital Bretonneau, medical intensive care unit

馃嚝馃嚪

Tours, France

漏 Copyright 2025. All Rights Reserved by MedPath